NCT07867704Not yet recruiting
Feasibility and Efficiency Study for the Implementation of a New Screening Method for Patients With Acute Myeloid Leukemia, in Laboratory Practice
Feasibility and Efficiency Study for the Implementation of a New Screening Method for Patients With Acute Myeloid Leukemia, in Laboratory Practice RAMD (Rapid AML Mutations Detection)
Source: ClinicalTrials.gov · Last updated 9 Oct 2026
Brief summary (registry, in English)
Prospective, multicenter study for the non-inferiority assessment of RAMD compared to GSS in determining the prognostic risk category according to ELN2022 for newly diagnosed AML patients on blood samples.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- First submitted
- 5 Oct 2026
- Start date
- Jan 2027
- Primary completion date
- Jan 2029
- Lead sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT07867704
What you commit to
- Study type: Interventional
- Planned participants: 75
- From Jan 2027 to the primary completion date, Jan 2029
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- 1\. Diagnosis of secondary AML
Who the study is looking for
- Patients with de novo AML, includind Acute Promyelocytic Leukemia (APL), untreated, newly diagnosed according to WHO/ICC 2022 criteria based on conventional cytological, cytogenetic, and immunophenotypic disease characterization
- Signed written informed consent according to ICH/EU/GCP and national local laws.
- Availability of 1 aliquot of White Blood Cells pellet (≥3x106 WBCs or purified from ≥1.5mL of blood) from bone marrow (BM) or peripheral blood (PB) collected at diagnosis for RAMD. The aliquot should be stored at -90°C until shipment.
- Age ≥ 18 years
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.